Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 271

1.

KRAS-Driven Lung Adenocarcinoma and B Cell Infiltration: Novel Insights for Immunotherapy.

Pinto R, Petriella D, Lacalamita R, Montrone M, Catino A, Pizzutilo P, Botticella MA, Zito FA, Del Bene G, Zonno A, Tommasi S, De Summa S.

Cancers (Basel). 2019 Aug 9;11(8). pii: E1145. doi: 10.3390/cancers11081145.

2.

DNA Hydroxymethylation at the Interface of the Environment and Nonalcoholic Fatty Liver Disease.

Tommasi S, Besaratinia A.

Int J Environ Res Public Health. 2019 Aug 5;16(15). pii: E2791. doi: 10.3390/ijerph16152791. Review.

3.

Exhaled breath condensate biomarkers for lung cancer.

Campanella A, De Summa S, Tommasi S.

J Breath Res. 2019 Aug 20;13(4):044002. doi: 10.1088/1752-7163/ab2f9f.

PMID:
31282387
4.

BRCA germline mutation test for all woman with ovarian cancer?

Paradiso AV, Digennaro M, Patruno M, De Summa S, Tommasi S, Berindan-Neagoe I.

BMC Cancer. 2019 Jun 28;19(1):641. doi: 10.1186/s12885-019-5829-4.

5.

Molecular Characterization of a Long-Term Survivor Double Metastatic Non-Small Cell Lung Cancer and Pancreatic Ductal Adenocarcinoma Treated with Gefitinib in Combination with Gemcitabine Plus Nab-Paclitaxel and mFOLFOX6 as First and Second Line Therapy.

Brunetti O, Badalamenti G, De Summa S, Calabrese A, Argentiero A, Fucci L, Longo V, Galetta D, Perrotti PMS, Pinto R, Petriella D, Danza K, Tommasi S, Leonetti F, Silvestris N.

Cancers (Basel). 2019 May 29;11(6). pii: E749. doi: 10.3390/cancers11060749.

6.

The Italian Rare Pancreatic Exocrine Cancer Initiative.

Brunetti O, Luchini C, Argentiero A, Tommasi S, Mangia A, Aprile G, Marchetti P, Vasile E, Casadei Gardini A, Scartozzi M, Barni S, Delfanti S, De Vita F, Di Costanzo F, Milella M, Cella CA, Berardi R, Cataldo I, Santini D, Doglioni C, Maiello E, Lawlor RT, Mazzaferro V, Lonardi S, Giuliante F, Brandi G, Scarpa A, Cascinu S, Silvestris N.

Tumori. 2019 Aug;105(4):353-358. doi: 10.1177/0300891619839461. Epub 2019 Apr 9.

PMID:
30967031
7.

Structure-guided design of antibacterials that allosterically inhibit DNA gyrase.

Thalji RK, Raha K, Andreotti D, Checchia A, Cui H, Meneghelli G, Profeta R, Tonelli F, Tommasi S, Bakshi T, Donovan BT, Howells A, Jain S, Nixon C, Quinque G, McCloskey L, Bax BD, Neu M, Chan PF, Stavenger RA.

Bioorg Med Chem Lett. 2019 Jun 1;29(11):1407-1412. doi: 10.1016/j.bmcl.2019.03.029. Epub 2019 Mar 22.

PMID:
30962087
8.

Plasma-activated medium triggers cell death and the presentation of immune activating danger signals in melanoma and pancreatic cancer cells.

Azzariti A, Iacobazzi RM, Di Fonte R, Porcelli L, Gristina R, Favia P, Fracassi F, Trizio I, Silvestris N, Guida G, Tommasi S, Sardella E.

Sci Rep. 2019 Mar 11;9(1):4099. doi: 10.1038/s41598-019-40637-z.

9.

Deregulation of Biologically Significant Genes and Associated Molecular Pathways in the Oral Epithelium of Electronic Cigarette Users.

Tommasi S, Caliri AW, Caceres A, Moreno DE, Li M, Chen Y, Siegmund KD, Besaratinia A.

Int J Mol Sci. 2019 Feb 10;20(3). pii: E738. doi: 10.3390/ijms20030738.

10.

Author Correction: Landscape of somatic mutations in 560 breast cancer whole-genome sequences.

Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, Martincorena I, Alexandrov LB, Martin S, Wedge DC, Van Loo P, Ju YS, Smid M, Brinkman AB, Morganella S, Aure MR, Lingjærde OC, Langerød A, Ringnér M, Ahn SM, Boyault S, Brock JE, Broeks A, Butler A, Desmedt C, Dirix L, Dronov S, Fatima A, Foekens JA, Gerstung M, Hooijer GKJ, Jang SJ, Jones DR, Kim HY, King TA, Krishnamurthy S, Lee HJ, Lee JY, Li Y, McLaren S, Menzies A, Mustonen V, O'Meara S, Pauporté I, Pivot X, Purdie CA, Raine K, Ramakrishnan K, Rodríguez-González FG, Romieu G, Sieuwerts AM, Simpson PT, Shepherd R, Stebbings L, Stefansson OA, Teague J, Tommasi S, Treilleux I, Van den Eynden GG, Vermeulen P, Vincent-Salomon A, Yates L, Caldas C, Van't Veer L, Tutt A, Knappskog S, Tan BKT, Jonkers J, Borg Å, Ueno NT, Sotiriou C, Viari A, Futreal PA, Campbell PJ, Span PN, Van Laere S, Lakhani SR, Eyfjord JE, Thompson AM, Birney E, Stunnenberg HG, van de Vijver MJ, Martens JWM, Børresen-Dale AL, Richardson AL, Kong G, Thomas G, Stratton MR.

Nature. 2019 Feb;566(7742):E1. doi: 10.1038/s41586-019-0883-2.

PMID:
30659290
11.

Translational control mechanisms in cutaneous malignant melanoma: the role of eIF2α.

Maida I, Zanna P, Guida S, Ferretta A, Cocco T, Palese LL, Londei P, Benelli D, Azzariti A, Tommasi S, Guida M, Pellacani G, Guida G.

J Transl Med. 2019 Jan 11;17(1):20. doi: 10.1186/s12967-019-1772-z.

12.

Small molecule inhibition of DDAH1 significantly attenuates triple negative breast cancer cell vasculogenic mimicry in vitro.

Hulin JA, Tommasi S, Elliot D, Mangoni AA.

Biomed Pharmacother. 2019 Mar;111:602-612. doi: 10.1016/j.biopha.2018.12.117. Epub 2019 Jan 3.

13.

Contribution of MUTYH Variants to Male Breast Cancer Risk: Results From a Multicenter Study in Italy.

Rizzolo P, Silvestri V, Bucalo A, Zelli V, Valentini V, Catucci I, Zanna I, Masala G, Bianchi S, Spinelli AM, Tommasi S, Tibiletti MG, Russo A, Varesco L, Coppa A, Calistri D, Cortesi L, Viel A, Bonanni B, Azzollini J, Manoukian S, Montagna M, Radice P, Palli D, Peterlongo P, Ottini L.

Front Oncol. 2018 Dec 4;8:583. doi: 10.3389/fonc.2018.00583. eCollection 2018.

14.

Discordance between FISH, IHC, and NGS Analysis of ALK Status in Advanced Non-Small Cell Lung Cancer (NSCLC): a Brief Report of 7 Cases.

Scattone A, Catino A, Schirosi L, Caldarola L, Tommasi S, Lacalamita R, Montagna ES, Galetta D, Serio G, Zito FA, Mangia A.

Transl Oncol. 2019 Feb;12(2):389-395. doi: 10.1016/j.tranon.2018.11.006. Epub 2018 Dec 4.

15.

Repurposing existing drugs for cardiovascular risk management: a focus on methotrexate.

Mangoni AA, Tommasi S, Zinellu A, Sotgia S, Carru C, Piga M, Erre GL.

Drugs Context. 2018 Nov 14;7:212557. doi: 10.7573/dic.212557. eCollection 2018. Review.

16.

Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study.

Pistillo MP, Fontana V, Morabito A, Dozin B, Laurent S, Carosio R, Banelli B, Ferrero F, Spano L, Tanda E, Ferrucci PF, Martinoli C, Cocorocchio E, Guida M, Tommasi S, De Galitiis F, Pagani E, Antonini Cappellini GC, Marchetti P, Quaglino P, Fava P, Osella-Abate S, Ascierto PA, Capone M, Simeone E, Romani M, Spagnolo F, Queirolo P; Italian Melanoma Intergroup (IMI).

Cancer Immunol Immunother. 2019 Jan;68(1):97-107. doi: 10.1007/s00262-018-2258-1. Epub 2018 Oct 11.

PMID:
30311027
17.

Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue.

Ciavarella S, Vegliante MC, Fabbri M, De Summa S, Melle F, Motta G, De Iuliis V, Opinto G, Enjuanes A, Rega S, Gulino A, Agostinelli C, Scattone A, Tommasi S, Mangia A, Mele F, Simone G, Zito AF, Ingravallo G, Vitolo U, Chiappella A, Tarella C, Gianni AM, Rambaldi A, Zinzani PL, Casadei B, Derenzini E, Loseto G, Pileri A, Tabanelli V, Fiori S, Rivas-Delgado A, López-Guillermo A, Venesio T, Sapino A, Campo E, Tripodo C, Guarini A, Pileri SA.

Ann Oncol. 2018 Dec 1;29(12):2363-2370. doi: 10.1093/annonc/mdy450.

18.

Standardization of CTC AR-V7 PCR assay and evaluation of its role in castration resistant prostate cancer progression.

Tommasi S, Pilato B, Carella C, Lasorella A, Danza K, Vallini I, De Summa S, Naglieri E.

Prostate. 2019 Jan;79(1):54-61. doi: 10.1002/pros.23710. Epub 2018 Aug 23.

PMID:
30141201
19.

The Lambda Select cII Mutation Detection System.

Besaratinia A, Tommasi S.

J Vis Exp. 2018 Apr 26;(134). doi: 10.3791/57510.

20.

The search for a melanoma-tailored chemotherapy in the new era of personalized therapy: a phase II study of chemo-modulating temozolomide followed by fotemustine and a cooperative study of GOIM (Gruppo Oncologico Italia Meridionale).

Guida M, Tommasi S, Strippoli S, Natalicchio MI, De Summa S, Pinto R, Cramarossa A, Albano A, Pisconti S, Aieta M, Ridolfi R, Azzariti A, Guida G, Lorusso V, Colucci G.

BMC Cancer. 2018 May 10;18(1):552. doi: 10.1186/s12885-018-4479-2.

21.

CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab.

Queirolo P, Dozin B, Morabito A, Banelli B, Carosio R, Fontana V, Ferrucci PF, Martinoli C, Cocorocchio E, Ascierto PA, Madonna G, Simeone E, De Galitiis F, Antonini Cappellini GC, Marchetti P, Guida M, Tommasi S, Ghilardi L, Merelli B, Fava P, Osella-Abate S, Guidoboni M, Romani M, Ferone D, Spagnolo F, Pistillo MP; Italian Melanoma Intergroup (IMI).

Eur J Cancer. 2018 Jul;97:59-61. doi: 10.1016/j.ejca.2018.04.005. Epub 2018 May 7. No abstract available.

PMID:
29743138
22.

Sex Differences in the Associations between L-Arginine Pathway Metabolites, Skeletal Muscle Mass and Function, and their Responses to Resistance Exercise, in Old Age.

Da Boit M, Tommasi S, Elliot D, Zinellu A, Sotgia S, Sibson R, Meakin JR, Aspden RM, Carru C, Mangoni AA, Gray SR.

J Nutr Health Aging. 2018;22(4):534-540. doi: 10.1007/s12603-017-0964-6.

PMID:
29582894
23.

Immunological mutational signature in adenosquamous cancer of pancreas: an exploratory study of potentially therapeutic targets.

Silvestris N, Brunetti O, Pinto R, Petriella D, Argentiero A, Fucci L, Tommasi S, Danza K, De Summa S.

Expert Opin Ther Targets. 2018 May;22(5):453-461. doi: 10.1080/14728222.2018.1456530. Epub 2018 Mar 27.

PMID:
29561217
24.

Corrigendum: Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study.

Queirolo P, Dozin B, Morabito A, Banelli B, Piccioli P, Fava C, Leo C, Carosio R, Laurent S, Fontana V, Ferrucci PF, Martinoli C, Cocorocchio E, Battaglia A, Ascierto PA, Capone M, Simeone E, De Galitiis F, Pagani E, Antonini Cappellini GC, Marchetti P, Guida M, Tommasi S, Mandalà M, Merelli B, Quaglino P, Fava P, Guidoboni M, Romani M, Spagnolo F, Pistillo MP.

Front Immunol. 2018 Mar 2;9:403. doi: 10.3389/fimmu.2018.00403. eCollection 2018.

25.

Homoarginine and inhibition of human arginase activity: kinetic characterization and biological relevance.

Tommasi S, Elliot DJ, Da Boit M, Gray SR, Lewis BC, Mangoni AA.

Sci Rep. 2018 Feb 27;8(1):3697. doi: 10.1038/s41598-018-22099-x.

26.

Mutation Analysis in Cultured Cells of Transgenic Rodents.

Besaratinia A, Zheng A, Bates SE, Tommasi S.

Int J Mol Sci. 2018 Jan 16;19(1). pii: E262. doi: 10.3390/ijms19010262.

27.

A possible role of FANCM mutations in male breast cancer susceptibility: Results from a multicenter study in Italy.

Silvestri V, Rizzolo P, Zelli V, Valentini V, Zanna I, Bianchi S, Tibiletti MG, Varesco L, Russo A, Tommasi S, Coppa A, Capalbo C, Calistri D, Viel A, Cortesi L, Manoukian S, Bonanni B, Montagna M, Palli D, Radice P, Peterlongo P, Ottini L.

Breast. 2018 Apr;38:92-97. doi: 10.1016/j.breast.2017.12.013. Epub 2018 Jan 4.

PMID:
29287190
28.

Adipokines in hereditary breast cancer patients and healthy relatives.

Sambiasi D, De Summa S, Digennaro M, Pilato B, Paradiso A, Tommasi S.

Oncotarget. 2017 Sep 18;8(60):101255-101261. doi: 10.18632/oncotarget.21018. eCollection 2017 Nov 24.

29.

Angiogenesis in adenosquamous cancer of pancreas.

Silvestris N, Danza K, Longo V, Brunetti O, Fucci L, Argentiero A, Calabrese A, Cataldo I, Tamma R, Ribatti D, Tommasi S.

Oncotarget. 2017 Sep 27;8(56):95773-95779. doi: 10.18632/oncotarget.21319. eCollection 2017 Nov 10.

30.

Limited mutagenicity of electronic cigarettes in mouse or human cells in vitro.

Tommasi S, Bates SE, Behar RZ, Talbot P, Besaratinia A.

Lung Cancer. 2017 Oct;112:41-46. doi: 10.1016/j.lungcan.2017.07.035. Epub 2017 Aug 3.

31.

MiR-193b regulates breast cancer cell migration and vasculogenic mimicry by targeting dimethylarginine dimethylaminohydrolase 1.

Hulin JA, Tommasi S, Elliot D, Hu DG, Lewis BC, Mangoni AA.

Sci Rep. 2017 Oct 25;7(1):13996. doi: 10.1038/s41598-017-14454-1.

32.

A Comparative Assessment of Quality of Life in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Through an Outpatient and Inpatient Model.

Martino M, Ciavarella S, De Summa S, Russo L, Meliambro N, Imbalzano L, Gallo GA, Moscato T, Messina G, Ferreri A, Cuzzola M, Irrera G, Naso V, Cimminiello M, Console G, Loseto G, Tommasi S, Guarini A.

Biol Blood Marrow Transplant. 2018 Mar;24(3):608-613. doi: 10.1016/j.bbmt.2017.09.021. Epub 2017 Oct 13.

33.

Six low-penetrance SNPs for the estimation of breast cancer heritability: A family-based study in Caucasian Italian patients.

De Summa S, Graziano F, Pilato B, Pinto R, Danza K, Lacalamita R, Serratì S, Sambiasi D, Grassi M, Tommasi S.

Oncol Lett. 2017 Oct;14(4):4384-4390. doi: 10.3892/ol.2017.6725. Epub 2017 Aug 4.

34.

Methotrexate, blood pressure and markers of arterial function in patients with rheumatoid arthritis: a repeated cross-sectional study.

Mangoni AA, Baghdadi LR, Shanahan EM, Wiese MD, Tommasi S, Elliot D, Woodman RJ.

Ther Adv Musculoskelet Dis. 2017 Sep;9(9):213-229. doi: 10.1177/1759720X17719850. Epub 2017 Aug 1.

35.

A Versatile Assay for Detection of Aberrant DNA Methylation in Bladder Cancer.

Tommasi S, Besaratinia A.

Methods Mol Biol. 2018;1655:29-41. doi: 10.1007/978-1-4939-7234-0_3.

36.

TGFbeta and miRNA regulation in familial and sporadic breast cancer.

Danza K, De Summa S, Pinto R, Pilato B, Palumbo O, Carella M, Popescu O, Digennaro M, Lacalamita R, Tommasi S.

Oncotarget. 2017 Jan 30;8(31):50715-50723. doi: 10.18632/oncotarget.14899. eCollection 2017 Aug 1.

37.

An opportune and unique research to evaluate the public health impact of electronic cigarettes.

Besaratinia A, Tommasi S.

Cancer Causes Control. 2017 Oct;28(10):1167-1171. doi: 10.1007/s10552-017-0952-5. Epub 2017 Aug 31.

38.

VEGF and TWIST1 in a 16-biomarker immunoprofile useful for prognosis of breast cancer patients.

Schirosi L, De Summa S, Tommasi S, Paradiso A, Gasparini G, Popescu O, Simone G, Mangia A.

Int J Cancer. 2017 Nov 1;141(9):1901-1911. doi: 10.1002/ijc.30868. Epub 2017 Jul 20.

39.
40.

Hereditary and non-hereditary branches of family eligible for BRCA test: cancers in other sites.

Digennaro M, Sambiasi D, Tommasi S, Pilato B, Diotaiuti S, Kardhashi A, Trojano G, Tufaro A, Paradiso AV.

Hered Cancer Clin Pract. 2017 May 25;15:7. doi: 10.1186/s13053-017-0067-8. eCollection 2017.

41.

Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores.

Lecarpentier J, Silvestri V, Kuchenbaecker KB, Barrowdale D, Dennis J, McGuffog L, Soucy P, Leslie G, Rizzolo P, Navazio AS, Valentini V, Zelli V, Lee A, Amin Al Olama A, Tyrer JP, Southey M, John EM, Conner TA, Goldgar DE, Buys SS, Janavicius R, Steele L, Ding YC, Neuhausen SL, Hansen TVO, Osorio A, Weitzel JN, Toss A, Medici V, Cortesi L, Zanna I, Palli D, Radice P, Manoukian S, Peissel B, Azzollini J, Viel A, Cini G, Damante G, Tommasi S, Peterlongo P, Fostira F, Hamann U, Evans DG, Henderson A, Brewer C, Eccles D, Cook J, Ong KR, Walker L, Side LE, Porteous ME, Davidson R, Hodgson S, Frost D, Adlard J, Izatt L, Eeles R, Ellis S, Tischkowitz M; EMBRACE, Godwin AK, Meindl A, Gehrig A, Dworniczak B, Sutter C, Engel C, Niederacher D, Steinemann D, Hahnen E, Hauke J, Rhiem K, Kast K, Arnold N, Ditsch N, Wang-Gohrke S, Wappenschmidt B, Wand D, Lasset C, Stoppa-Lyonnet D, Belotti M, Damiola F, Barjhoux L, Mazoyer S; GEMO Study Collaborators, Van Heetvelde M, Poppe B, De Leeneer K, Claes KBM, de la Hoya M, Garcia-Barberan V, Caldes T, Perez Segura P, Kiiski JI, Aittomäki K, Khan S, Nevanlinna H, van Asperen CJ; HEBON, Vaszko T, Kasler M, Olah E, Balmaña J, Gutiérrez-Enríquez S, Diez O, Teulé A, Izquierdo A, Darder E, Brunet J, Del Valle J, Feliubadalo L, Pujana MA, Lazaro C, Arason A, Agnarsson BA, Johannsson OT, Barkardottir RB, Alducci E, Tognazzo S, Montagna M, Teixeira MR, Pinto P, Spurdle AB, Holland H; KConFab Investigators, Lee JW, Lee MH, Lee J, Kim SW, Kang E, Kim Z, Sharma P, Rebbeck TR, Vijai J, Robson M, Lincoln A, Musinsky J, Gaddam P, Tan YY, Berger A, Singer CF, Loud JT, Greene MH, Mulligan AM, Glendon G, Andrulis IL, Toland AE, Senter L, Bojesen A, Nielsen HR, Skytte AB, Sunde L, Jensen UB, Pedersen IS, Krogh L, Kruse TA, Caligo MA, Yoon SY, Teo SH, von Wachenfeldt A, Huo D, Nielsen SM, Olopade OI, Nathanson KL, Domchek SM, Lorenchick C, Jankowitz RC, Campbell I, James P, Mitchell G, Orr N, Park SK, Thomassen M, Offit K, Couch FJ, Simard J, Easton DF, Chenevix-Trench G, Schmutzler RK, Antoniou AC, Ottini L.

J Clin Oncol. 2017 Jul 10;35(20):2240-2250. doi: 10.1200/JCO.2016.69.4935. Epub 2017 Apr 27.

42.

Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study.

Queirolo P, Dozin B, Morabito A, Banelli B, Piccioli P, Fava C, Leo C, Carosio R, Laurent S, Fontana V, Ferrucci PF, Martinoli C, Cocorocchio E, Battaglia A, Ascierto PA, Capone M, Simeone E, De Galitiis F, Pagani E, Antonini Cappellini GC, Marchetti P, Guida M, Tommasi S, Mandalà M, Merelli B, Quaglino P, Fava P, Guidoboni M, Romani M, Spagnolo F, Pistillo MP.

Front Immunol. 2017 Apr 12;8:386. doi: 10.3389/fimmu.2017.00386. eCollection 2017. Erratum in: Front Immunol. 2018 Mar 02;9:403.

43.

Comment on 'Renewed interest in the progesterone receptor in breast cancer'.

Simone G, Diotaiuti S, Digennaro M, Sambiasi D, De Summa S, Tommasi S, Altieri R, Mangia A, Dantona C, Paradiso A.

Br J Cancer. 2017 Jul 11;117(2):e1. doi: 10.1038/bjc.2017.90. Epub 2017 Apr 11. No abstract available.

44.

GATK hard filtering: tunable parameters to improve variant calling for next generation sequencing targeted gene panel data.

De Summa S, Malerba G, Pinto R, Mori A, Mijatovic V, Tommasi S.

BMC Bioinformatics. 2017 Mar 23;18(Suppl 5):119. doi: 10.1186/s12859-017-1537-8.

45.

u-PAR expression in cancer associated fibroblast: new acquisitions in multiple myeloma progression.

Ciavarella S, Laurenzana A, De Summa S, Pilato B, Chillà A, Lacalamita R, Minoia C, Margheri F, Iacobazzi A, Rana A, Merchionne F, Fibbi G, Del Rosso M, Guarini A, Tommasi S, Serratì S.

BMC Cancer. 2017 Mar 24;17(1):215. doi: 10.1186/s12885-017-3183-y.

46.

Next-generation sequencing: advances and applications in cancer diagnosis.

Serratì S, De Summa S, Pilato B, Petriella D, Lacalamita R, Tommasi S, Pinto R.

Onco Targets Ther. 2016 Dec 2;9:7355-7365. eCollection 2016. Review.

47.

Genetic profiling of a rare condition: co-occurrence of albinism and multiple primary melanoma in a Caucasian family.

De Summa S, Guida M, Tommasi S, Strippoli S, Pellegrini C, Fargnoli MC, Pilato B, Natalicchio I, Guida G, Pinto R.

Oncotarget. 2017 May 2;8(18):29751-29759. doi: 10.18632/oncotarget.12777.

48.

β-catenin interaction with NHERF1 and RASSF1A methylation in metastatic colorectal cancer patients.

Schirosi L, Mazzotta A, Opinto G, Pinto R, Graziano G, Tommasi S, Fucci L, Simone G, Mangia A.

Oncotarget. 2016 Oct 18;7(42):67841-67850. doi: 10.18632/oncotarget.12280.

49.

Somatic alterations of targetable oncogenes are frequently observed in BRCA1/2 mutation negative male breast cancers.

Rizzolo P, Navazio AS, Silvestri V, Valentini V, Zelli V, Zanna I, Masala G, Bianchi S, Scarnò M, Tommasi S, Palli D, Ottini L.

Oncotarget. 2016 Nov 8;7(45):74097-74106. doi: 10.18632/oncotarget.12272.

50.

Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration.

Smid M, Rodríguez-González FG, Sieuwerts AM, Salgado R, Prager-Van der Smissen WJ, Vlugt-Daane MV, van Galen A, Nik-Zainal S, Staaf J, Brinkman AB, van de Vijver MJ, Richardson AL, Fatima A, Berentsen K, Butler A, Martin S, Davies HR, Debets R, Gelder ME, van Deurzen CH, MacGrogan G, Van den Eynden GG, Purdie C, Thompson AM, Caldas C, Span PN, Simpson PT, Lakhani SR, Van Laere S, Desmedt C, Ringnér M, Tommasi S, Eyford J, Broeks A, Vincent-Salomon A, Futreal PA, Knappskog S, King T, Thomas G, Viari A, Langerød A, Børresen-Dale AL, Birney E, Stunnenberg HG, Stratton M, Foekens JA, Martens JW.

Nat Commun. 2016 Sep 26;7:12910. doi: 10.1038/ncomms12910.

Supplemental Content

Loading ...
Support Center